Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-80948543 + JNJ-75348780
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
JNJ-80948543 + JNJ-75348780 is an investigational combination therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The regimen consists of JNJ-80948543, a trispecific T-cell–redirecting antibody targeting CD79b, CD20, and CD3, and JNJ-75348780, a bispecific antibody targeting CD22 and CD3. Both agents aim to engage and redirect T cells toward B cells expressing their respective antigens, with the goal of enhancing cytotoxic immune responses against malignant B cells in B-cell non-Hodgkin lymphoid malignancies. JNJ-80948543 is administered subcutaneously or intravenously, and JNJ-75348780 is administered subcutaneously. The combination is undergoing Phase 1b clinical trials to determine the recommended Phase 2 regimen and to establish safety and preliminary efficacy in adults with relapsed/refractory B-cell NHL[1][3][5].
02
Targets
CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chain
Beyond the preview
Go deeper on JNJ-80948543 + JNJ-75348780.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-80948543 + JNJ-75348780.